Russia Generics Market Summary, Competitive Analysis and Forecast to 2027

Key Highlights

• For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. The market value is evaluated at ex-factory prices.
• The Russian generics market had total revenues of $11.9 billion in 2022, representing a compound annual growth rate (CAGR) of 11.6% between 2017 and 2022.
• Market consumption volume increased with a CAGR of 3.5% between 2017 and 2022, to reach a total of 78.1 % in 2022.
• The performance of the market is forecast to decelerate, with an anticipated CAGR of 9% for the five-year period 2022 - 2027, which is expected to drive the market to a value of $18.3 billion by the end of 2027.

Scope

• Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Russia
• Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Russia
• Leading company profiles reveal details of key generics market players’ global operations and financial performance
• Add weight to presentations and pitches by understanding the future growth prospects of the Russia generics market with five year forecasts

Reasons to Buy

• What was the size of the Russia generics market by value in 2022?
• What will be the size of the Russia generics market in 2027?
• What factors are affecting the strength of competition in the Russia generics market?
• How has the market performed over the last five years?
• What are the main segments that make up Russia's generics market?